Literature DB >> 11805341

The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.

Luc Jasmin1, Duc Tien, David Weinshenker, Richard D Palmiter, Paul G Green, Gabriella Janni, Peter T Ohara.   

Abstract

Noradrenaline (NA), a key neurotransmitter of the endogenous pain inhibitory system, acutely inhibits nociceptive transmission (including that mediated by substance P), potentiates opioid analgesia, and underlies part of the antinociceptive effects of the widely prescribed tricyclic antidepressants. Lesions of noradrenergic neurons, however, result in either normal or reduced pain behavior and variable changes in morphine antinociception, undermining the proposed association between noradrenaline (NA) deficiency and chronic pain (hyperalgesia). We used mice lacking the gene coding for dopamine beta-hydroxylase, the enzyme responsible for synthesis of NA from dopamine, to reexamine the consequences of a lack of NA on pain behavior. Here, we show that absence of NA in the central nervous system results in a substance P-mediated chronic hyperalgesia (decreased nociceptive threshold) to thermal, but not mechanical, stimuli and decreased efficacy of morphine. Contrary to studies that show substance P-mediated hyperalgesia requires intense stimuli, we found that even a mild stimulus is sufficient to evoke substance P-dependent hyperalgesia in the NA-deficient mice. Restoring central NA normalized both the nociceptive threshold and morphine efficacy, which is consistent with a tonic inhibitory effect of NA on nociceptive transmission. Unexpectedly, however, antagonists to the substance P receptor (the NK1 receptor) could achieve the same effect as NA replacement. We conclude that when unopposed by NA, substance P acting at the NK1 receptor causes chronic thermal hyperalgesia, and that the reduced opioid efficacy associated with a lack of NA is due to increased NK1-receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805341      PMCID: PMC117425          DOI: 10.1073/pnas.012598599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome.

Authors:  R Staud; C J Vierck; R L Cannon; A P Mauderli; D D Price
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

2.  Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord.

Authors:  M Malcangio; M S Ramer; T J Boucher; S B McMahon
Journal:  Eur J Neurosci       Date:  2000-01       Impact factor: 3.386

Review 3.  Wind-up of spinal cord neurones and pain sensation: much ado about something?

Authors:  J F Herrero; J M Laird; J A López-García
Journal:  Prog Neurobiol       Date:  2000-06       Impact factor: 11.685

Review 4.  Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry.

Authors:  A I Basbaum; H L Fields
Journal:  Annu Rev Neurosci       Date:  1984       Impact factor: 12.449

5.  Effect of intrathecally administered noradrenergic antagonists on nociception in the rat.

Authors:  J Sagen; H K Proudfit
Journal:  Brain Res       Date:  1984-09-24       Impact factor: 3.252

6.  Limited involvement of central noradrenergic pathways in morphine-induced antinociception.

Authors:  O G Berge; S O Ogren
Journal:  Neuropharmacology       Date:  1984-10       Impact factor: 5.250

7.  Intrathecal DSP4 selectively depletes spinal noradrenaline and attenuates morphine analgesia.

Authors:  F X Zhong; X Q Ji; K Tsou
Journal:  Eur J Pharmacol       Date:  1985-10-22       Impact factor: 4.432

8.  Noradrenergic inhibition of the release of substance P from the primary afferents in the rabbit spinal dorsal horn.

Authors:  Y Kuraishi; N Hirota; Y Sato; S Kaneko; M Satoh; H Takagi
Journal:  Brain Res       Date:  1985-12-16       Impact factor: 3.252

9.  Substance P, injected intrathecally, antagonizes the spinal antinociceptive effect of morphine, baclofen and noradrenaline.

Authors:  J Sawynok; S M Moochhala; D J Pillay
Journal:  Neuropharmacology       Date:  1984-07       Impact factor: 5.250

Review 10.  Classification, epidemiology, and natural history of fibromyalgia.

Authors:  K P White; M Harth
Journal:  Curr Pain Headache Rep       Date:  2001-08
View more
  28 in total

1.  Substance P, opioid, and catecholamine systems in the mouse central nervous system (CNS).

Authors:  R G Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Abnormal development of the locus coeruleus in Ear2(Nr2f6)-deficient mice impairs the functionality of the forebrain clock and affects nociception.

Authors:  Marei Warnecke; Henrik Oster; Jean-Pierre Revelli; Gonzalo Alvarez-Bolado; Gregor Eichele
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

3.  Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.

Authors:  Jie Xiao; Si Zeng; Xiangrui Wang; Hasan Babazada; Zhanchun Li; Renyu Liu; Weifeng Yu
Journal:  Transl Perioper Pain Med       Date:  2016

Review 4.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 5.  Central modulation of pain.

Authors:  Michael H Ossipov; Gregory O Dussor; Frank Porreca
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

6.  A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception.

Authors:  F S Hall; J M Schwarzbaum; M T G Perona; J S Templin; M G Caron; K-P Lesch; D L Murphy; G R Uhl
Journal:  Neuroscience       Date:  2010-12-01       Impact factor: 3.590

7.  Trigeminal neuroplasticity underlies allodynia in a preclinical model of mild closed head traumatic brain injury (cTBI).

Authors:  Golam Mustafa; Jiamei Hou; Shigeharu Tsuda; Rachel Nelson; Ankita Sinharoy; Zachary Wilkie; Rahul Pandey; Robert M Caudle; John K Neubert; Floyd J Thompson; Prodip Bose
Journal:  Neuropharmacology       Date:  2016-03-10       Impact factor: 5.250

8.  Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.

Authors:  Anne-Julie Chabot-Doré; Magali Millecamps; Lina Naso; Dominic Devost; Phan Trieu; Marjo Piltonen; Luda Diatchenko; Carolyn A Fairbanks; George L Wilcox; Terence E Hébert; Laura S Stone
Journal:  Neuropharmacology       Date:  2015-08-06       Impact factor: 5.250

9.  Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain.

Authors:  Diana S Meske; Jennifer Y Xie; Janice Oyarzo; Hamid Badghisi; Michael H Ossipov; Frank Porreca
Journal:  Neurosci Lett       Date:  2013-08-19       Impact factor: 3.046

Review 10.  Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.

Authors:  Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  Pharmacol Ther       Date:  2009-04-23       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.